Jubilant Life Sciences Q3 net profit at Rs 44 cr
Shares of both Jubilant Life Sciences and Jubilant Industries Limited are now listed on Bombay Stock Exchange and National Stock Exchange.
By PTI |
NEW DELHI: Jubilant Life Sciences today posted a consolidated net profit after minority interest of Rs 44.1 crore for the third quarter ended December 31, 2010, riding on the back of strong performance in generics business.
The company had posted a net profit of Rs 100.8 crore in the same period previous fiscal, Jubilant Life Sciences said in a statement.
The company's total income stood at Rs 870.6 crore for the third quarter ended December 31, 2010, while the same was Rs 964.1 crore in the same period last fiscal.
The results for the current quarter and nine months ended December 31, 2010 are for the businesses remaining with the company, post demerger/amalgamation, after giving effect to the scheme and accordingly, are not comparable with the previous quarter/period.
"The company witnessed high volume and capacity utilisation in products segment during the quarter and year-to-date across all products," Jubilant Life Sciences CMD Shyam S Bhartia said.
He further added: "There has been good growth in generics and active pharmaceutical ingredients (APIs) due to new product launches and market share gains."
In order to create a focused life science entity, the company has demerged its agri and performance polymers business into a separate entity, Jubilant Industries Limited.
Shares of both Jubilant Life Sciences and Jubilant Industries Limited are now listed on Bombay Stock Exchange and National Stock Exchange.
For the nine months ended December 31, 2010, the company posted a net profit (after minority interest) of Rs 168 crore, while the same was Rs 284.30 crore in the same period last fiscal.
Shares of Jubilant Life Sciences were trading at Rs 202.75 today on the Bombay Stock Exchange in the late afternoon trade, down 0.27 per cent from its previous close.
The company had posted a net profit of Rs 100.8 crore in the same period previous fiscal, Jubilant Life Sciences said in a statement.
The company's total income stood at Rs 870.6 crore for the third quarter ended December 31, 2010, while the same was Rs 964.1 crore in the same period last fiscal.
The results for the current quarter and nine months ended December 31, 2010 are for the businesses remaining with the company, post demerger/amalgamation, after giving effect to the scheme and accordingly, are not comparable with the previous quarter/period.
"The company witnessed high volume and capacity utilisation in products segment during the quarter and year-to-date across all products," Jubilant Life Sciences CMD Shyam S Bhartia said.
He further added: "There has been good growth in generics and active pharmaceutical ingredients (APIs) due to new product launches and market share gains."
ADVERTISEMENT
In order to create a focused life science entity, the company has demerged its agri and performance polymers business into a separate entity, Jubilant Industries Limited.
Shares of both Jubilant Life Sciences and Jubilant Industries Limited are now listed on Bombay Stock Exchange and National Stock Exchange.
For the nine months ended December 31, 2010, the company posted a net profit (after minority interest) of Rs 168 crore, while the same was Rs 284.30 crore in the same period last fiscal.
Shares of Jubilant Life Sciences were trading at Rs 202.75 today on the Bombay Stock Exchange in the late afternoon trade, down 0.27 per cent from its previous close.
Too busy to trade in stocks? Invest in Mutual Funds with ET Money!
Bookmark or read stories offline -
Download ET Markets APP
Download ET Markets APP
ADVERTISEMENT
